Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2009

Sørensen Rikke Baek, Andersen Rikke Sick, Svane Inge Marie, Engell-Noerregaard Lotte, Hadrup Sine R, Balslev Eva, Andersen Mads Hald, thor Straten Per

Abstract excerpt

PURPOSE: This study aimed to examine CD8 T-cell reactivity in breast cancer patients against cyclin B1-derived peptides restricted by the human leukocyte antigen (HLA)-A2 molecule. EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells from 36 breast cancer patients were analyzed by enzyme-linked immunosorbent spot (ELISPOT) for the presence of T cells recognizing the cyclin B1-derived peptides CB9 (AKYLMELTM)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Cyclin B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin B1

Share to Flow Cytometry

Share to HLA-A2 Antigen

Share to Immunoenzyme Techniques

Share to Interferon-gamma

Share to Peptide Fragments

Source

Identifiers

PMID: 19223507
DOI: 10.1158/1078-0432.CCR-08-1412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.PMID 19223507Read ↗

Wildtype p53-specific antibody and T-cell responses in cancer patients.Semantic proximity Read ↗

Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.Semantic proximity Read ↗

The role of tumor-associated antigens in the biology and immunotherapy of breast cancer.Semantic proximity Read ↗

Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patientsSemantic proximity Read ↗

Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Semantic proximity Read ↗

Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNASemantic proximity Read ↗

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53Semantic proximity Read ↗

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.Semantic proximity Read ↗

A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.Semantic proximity Read ↗

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Semantic proximity Read ↗

In Situ Detection of Individual Classic MHC-I Gene Products in Cancer.Semantic proximity Read ↗

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.